Safety Profile of Rapamycin Perfluorocarbon Nanoparticles for Preventing Cisplatin-Induced Kidney Injury
Authors:
- Qingyu ZhouQZQingyu Zhou
- Justin DohertyJDJustin Doherty
- Antonina AkkAAAntonina Akk
- Luke E. SpringerLSLuke E. Springer
- Ping FanPFPing Fan
- Ivan SpasojevicISIvan Spasojevic
- Ganesh V. HaladeGHGanesh V. Halade
- Huanghe YangHYHuanghe Yang
- Christine T. N. PhamCPChristine T. N. Pham
- Samuel A. WicklineSWSamuel A. Wickline
- Hua PanHPHua Pan
Open Access
- 21 January 2022
- journal article
- research article
- Published by MDPI AG in Nanomaterials
- Vol. 12 (3) , 336
Abstract
Cancer treatment-induced toxicities may restrict maximal effective dosing for treatment and cancer survivors’ quality of life. It is critical to develop novel strategies that mitigate treatment-induced toxicity without affecting the efficacy of anti-cancer therapies. Rapamycin is a macrolide with anti-cancer properties, but its clinical application has been hindered, partly by unfavorable bioavailability, pharmacokinetics, and side effects. As a result, significant efforts have been undertaken to develop a variety of nano-delivery systems for the effective and safe administration of rapamycin. While the efficacy of nanostructures carrying rapamycin has been studied intensively, the pharmacokinetics, biodistribution, and safety remain to be investigated. In this study, we demonstrate the potential for rapamycin perfluorocarbon (PFC) nanoparticles to mitigate cisplatin-induced acute kidney injury with a single preventative dose. Evaluations of pharmacokinetics and biodistribution suggest that the PFC nanoparticle delivery system improves rapamycin pharmacokinetics. The safety of rapamycin PFC nanoparticles was shown both in vitro and in vivo. After a single dose, no disturbance was observed in blood tests or cardiac functional evaluations. Repeated dosing of rapamycin PFC nanoparticles did not affect overall spleen T cell proliferation and responses to stimulation, although it significantly decreased the number of Foxp3+CD4+ T cells and NK1.1+ cells were observed.Keywords
Funding Information
- National Institutes of Health (P30 AR073752-01, HL132989, HL144788, DP2GM126898, R00NS086916, DK125322,HL154009)
This publication has 66 references indexed in Scilit:
- Development of a Physiologically‐Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A ContentCPT: Pharmacometrics & Systems Pharmacology, 2013
- Use of remote film loading methodology to entrap sirolimus into liposomes: Preparation, characterization and in vivo efficacy for treatment of restenosisInternational Journal of Pharmaceutics, 2011
- Selective Transcription in Response to an Inflammatory StimulusCell, 2010
- Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factorsEuropean Journal of Cancer, 2009
- Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKKGenes & Development, 2008
- Intramural Delivery of Rapamycin With α v β 3 -Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon InjuryArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycinCancer Chemotherapy and Pharmacology, 2007
- Chronic Health Conditions in Adult Survivors of Childhood CancerNew England Journal of Medicine, 2006
- Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant RecipientsClinical Pharmacokinetics, 2006
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975